Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting.
Nat Commun
November 2024
Institute of Transfusion Medicine - Transfusion Center, Johannes Gutenberg University Medical Center, 55131, Mainz, Germany.
Article Synopsis
- Fibrinolysis plays a crucial role in the release of hematopoietic stem cells from bone marrow, affecting the development of B-cell acute lymphoblastic leukemia (B-ALL).
- Activation of plasmin, driven by annexin A2, alters the extracellular matrix (ECM), which impacts cancer cell growth by trapping the growth factor IGF1 and hindering signaling pathways.
- Inhibiting plasmin activation with ε-aminocaproic acid (EACA) shows promise in reducing tumor size and extending survival in B-ALL models, suggesting that targeting fibrinolysis could be a helpful addition to cancer treatment.
Systematic review and meta-analysis of tranexamic acid and epsilon aminocaproic acid in pediatric heart surgery.
Kardiochir Torakochirurgia Pol
June 2024
LUXMED Group.
Antifibrinolytic and Adjunct Hemostatic Agents: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference.
Pediatr Crit Care Med
July 2024
Divisions of Hematology/Oncology and Critical Care, Department of Pediatrics, University of Minnesota, Minnesota, MN.
Objectives: To derive systematic-review informed, modified Delphi consensus regarding antifibrinolytic and adjunct hemostatic agents in neonates and children supported with extracorporeal membrane oxygenation (ECMO) for the Pediatric ECMO Anticoagulation CollaborativE consensus conference.
Data Sources: A structured literature search was performed using PubMed, EMBASE, and Cochrane Library (CENTRAL) databases from January 1988 to May 2021.
Study Selection: Use of antifibrinolytics (epsilon-aminocaproic acid [EACA] or tranexamic acid), recombinant factor VII activated (rFVIIa), or topical hemostatic agents (THAs).
Bleeding Reversal With Antifibrinolytics or Cryoprecipitate Following Thrombolysis for Acute Ischemic Stroke: A Case Series.
Adv Emerg Nurs J
May 2024
Author Affiliations: University of Kentucky HealthCare Pharmacy Services, Lexington, KY (Drs Platt Baum, Nestor, and Bailey); and Department of Emergency Medicine, University of Kentucky College of Medicine, Lexington, KY (D. Baum).
Patients who develop an intracerebral hemorrhage (ICH) following thrombolysis in acute ischemic stroke (AIS) have a mortality rate as high as 50%. Treatment options include blood products, such as cryoprecipitate, or antifibrinolytics, such as tranexamic acid (TXA) or ε-aminocaproic acid (EACA). Current guidelines recommend cryoprecipitate first-line despite limited data to support one agent over another.
View Article and Find Full Text PDFEfficacy and utility of antifibrinolytics in pediatric spine surgery: a systematic review and network meta-analysis.
Neurosurg Rev
April 2024
Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Antifibrinolytics have gained increasing attention in minimizing blood loss and mitigating the risks associated with massive transfusions, including infection and coagulopathy in pediatric patients undergoing spine surgery. Nevertheless, the selection of optimal agent is still a matter of debate. We aim to review the utility of these agents and compare the efficacy of antifibrinolytics in pediatric and adolescent spine surgeries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!